8-KLeadership ChangesExhibits & Filings

ORACLE CORP 8-K Report, Executive Changes (Jul 7, 2021)

Filed July 7, 2021For Securities:ORCLORCL-PD

Summary

Oracle Corporation (ORCL) filed an 8-K on July 6, 2021, reporting a significant amendment to performance stock options (PSOs) granted in 2017 to key executives, Chairman Larry Ellison and CEO Safra Catz. The amendment extends the performance period of these PSOs by three additional fiscal years, from May 31, 2022, to May 31, 2025. This extension provides an extended opportunity for these executives to meet remaining performance and market capitalization goals, potentially leading to the vesting of additional tranches of their PSOs. To date, one tranche of the PSOs has vested, having met the stock price goal and the first market capitalization goal. The extended performance period means that further vesting is contingent on achieving specified operational and market capitalization targets before the new May 31, 2025 deadline. Investors should note this as a potential driver for executive focus and alignment with long-term company performance and valuation.

Key Highlights

  • 1Amendment to Performance Stock Options (PSOs) for CEO Safra Catz and Chairman Larry Ellison approved on June 30, 2021.
  • 2The performance period for these PSOs has been extended by three fiscal years, now ending on May 31, 2025.
  • 3One tranche of the PSOs has already vested, meeting the stock price goal and the first market capitalization goal.
  • 4Additional tranches may vest if remaining operational and market capitalization performance goals are met before May 31, 2025.
  • 5This extension indicates continued executive incentive tied to Oracle's long-term financial and market performance.
  • 6The amended agreement is filed as Exhibit 10.15 to the 8-K.

Frequently Asked Questions

The 8-K filing announces an amendment to the Performance Stock Options (PSOs) granted to CEO Safra Catz and Chairman Larry Ellison. The primary change is the extension of the performance period for these options by three years, pushing the deadline to May 31, 2025.

Yes, one tranche (representing one-seventh) of the PSOs has already vested. This vesting occurred because the stock price goal and the first market capitalization goal were certified as achieved.

Additional tranches of the PSOs may vest if the remaining operational and market capitalization performance goals are met by May 31, 2025. The extension of the performance period provides more time for these goals to be achieved.

This amendment aligns the incentives of key executives with the company's long-term performance and market valuation. The extended timeline for vesting PSOs suggests continued focus on achieving specific operational and market cap targets through May 2025, which could be viewed positively by investors focused on sustained growth and value creation.